A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients with Amyotrophic Lateral Sclerosis (ALS)

  • Mathers, Susan (Primary Chief Investigator (PCI))

Project: Research

Project Details

Effective start/end date12/01/2111/01/26


  • clinical trial
  • treatment efficacy
  • treatment safety
  • amyotrophic lateral sclerosis